BACKGROUND: We hypothesized that immune mediator concentrations in the bronchoalveolar fluid (BALF) are predictive of bronchiolitis obliterans syndrome (BOS) and demonstrate specific patterns of dysregulation, depending on the presence of acute cellular rejection, BOS, aspiration, and timing of lung transplantation. STUDY DESIGN: We prospectively collected 257 BALF samples from 105 lung transplant recipients. The BALF samples were assessed for absolute and differential white blood cell counts and 34 proteins implicated in pulmonary immunity, inflammation, fibrosis, and aspiration. RESULTS: There were elevated BALF concentrations of interleukin (IL)-15, IL-17, basic fibroblast growth factor, tumor necrosis factor-α, and myeloperoxidase, and reduced concentrations of α1-antitrypsin, which were predictive of early-onset BOS. Patients with BOS had an increased percentage of BALF lymphocytes and neutrophils, with a reduced percentage of macrophages (p < 0.05). The BALF concentrations of IL-1β; IL-8; interferon-γ-induced protein 10; regulated upon activation, normal T-cell expressed and secreted; neutrophil elastase; and pepsin were higher in patients with BOS (p < 0.05). Among those with BOS, BALF concentrations of IL-1RA; IL-8; eotaxin; interferon-γ-induced protein 10; regulated upon activation, normal T-cell expressed and secreted; myeloperoxidase; and neutrophil elastase were positively correlated with time since transplantation (p < 0.01). Those with worse grades of acute cellular rejection had an increased percentage of lymphocytes in their BALF (p < 0.0001) and reduced BALF concentrations of IL-1β, IL-7, IL-9, IL-12, granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, interferon-γ, and vascular endothelial growth factor (p ≤ 0.001). Patients with aspiration based on detectable pepsin had increased percentage of neutrophils (p < 0.001) and reduced BALF concentrations of IL-12 (p < 0.001). CONCLUSIONS: The BALF levels of IL-15, IL-17, basic fibroblast growth factor, tumor necrosis factor-α, myeloperoxidase, and α1-antitrypsin at 6 to 12 months after lung transplantation are predictive of early-onset BOS, and those with BOS and aspiration have an augmented chemotactic and inflammatory balance of pulmonary leukocytes and immune mediators. These data justify the surgical prevention of aspiration and argue for the refinement of antirejection regimens.
BACKGROUND: We hypothesized that immune mediator concentrations in the bronchoalveolar fluid (BALF) are predictive of bronchiolitis obliterans syndrome (BOS) and demonstrate specific patterns of dysregulation, depending on the presence of acute cellular rejection, BOS, aspiration, and timing of lung transplantation. STUDY DESIGN: We prospectively collected 257 BALF samples from 105 lung transplant recipients. The BALF samples were assessed for absolute and differential white blood cell counts and 34 proteins implicated in pulmonary immunity, inflammation, fibrosis, and aspiration. RESULTS: There were elevated BALF concentrations of interleukin (IL)-15, IL-17, basic fibroblast growth factor, tumor necrosis factor-α, and myeloperoxidase, and reduced concentrations of α1-antitrypsin, which were predictive of early-onset BOS. Patients with BOS had an increased percentage of BALF lymphocytes and neutrophils, with a reduced percentage of macrophages (p < 0.05). The BALF concentrations of IL-1β; IL-8; interferon-γ-induced protein 10; regulated upon activation, normal T-cell expressed and secreted; neutrophil elastase; and pepsin were higher in patients with BOS (p < 0.05). Among those with BOS, BALF concentrations of IL-1RA; IL-8; eotaxin; interferon-γ-induced protein 10; regulated upon activation, normal T-cell expressed and secreted; myeloperoxidase; and neutrophil elastase were positively correlated with time since transplantation (p < 0.01). Those with worse grades of acute cellular rejection had an increased percentage of lymphocytes in their BALF (p < 0.0001) and reduced BALF concentrations of IL-1β, IL-7, IL-9, IL-12, granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, interferon-γ, and vascular endothelial growth factor (p ≤ 0.001). Patients with aspiration based on detectable pepsin had increased percentage of neutrophils (p < 0.001) and reduced BALF concentrations of IL-12 (p < 0.001). CONCLUSIONS: The BALF levels of IL-15, IL-17, basic fibroblast growth factor, tumor necrosis factor-α, myeloperoxidase, and α1-antitrypsin at 6 to 12 months after lung transplantation are predictive of early-onset BOS, and those with BOS and aspiration have an augmented chemotactic and inflammatory balance of pulmonary leukocytes and immune mediators. These data justify the surgical prevention of aspiration and argue for the refinement of antirejection regimens.
Authors: Marc Estenne; Janet R Maurer; Annette Boehler; James J Egan; Adaani Frost; Marshall Hertz; George B Mallory; Gregory I Snell; Samuel Yousem Journal: J Heart Lung Transplant Date: 2002-03 Impact factor: 10.247
Authors: C L Lau; S M Palmer; D N Howell; R McMahon; D Hadjiliadis; J Gaca; T N Pappas; R D Davis; S Eubanks Journal: Surg Endosc Date: 2002-07-29 Impact factor: 4.584
Authors: G C Riise; B A Andersson; C Kjellström; G Martensson; F N Nilsson; W Ryd; H Scherstén Journal: Eur Respir J Date: 1999-11 Impact factor: 16.671
Authors: P Marco Fisichella; Christopher S Davis; Erin Lowery; Matthew Pittman; James Gagermeier; Robert B Love; Elizabeth J Kovacs Journal: J Surg Res Date: 2012-04-18 Impact factor: 2.192
Authors: K C Meyer; D R Nunley; J H Dauber; A T Iacono; R J Keenan; R D Cornwell; R B Love Journal: Am J Respir Crit Care Med Date: 2001-07-01 Impact factor: 21.405
Authors: James K Stoller; Robert Fallat; Mark D Schluchter; Ralph G O'Brien; Jason T Connor; Nicholas Gross; Kevin O'Neil; Robert Sandhaus; Ronald G Crystal Journal: Chest Date: 2003-05 Impact factor: 9.410
Authors: R Duane Davis; Christine L Lau; Steve Eubanks; Robert H Messier; Denis Hadjiliadis; Mark P Steele; Scott M Palmer Journal: J Thorac Cardiovasc Surg Date: 2003-03 Impact factor: 5.209
Authors: Craig J Galbán; Jennifer L Boes; Maria Bule; Carrie L Kitko; Daniel R Couriel; Timothy D Johnson; Vihba Lama; Eef D Telenga; Maarten van den Berge; Alnawaz Rehemtulla; Ella A Kazerooni; Michael J Ponkowski; Brian D Ross; Gregory A Yanik Journal: Biol Blood Marrow Transplant Date: 2014-06-18 Impact factor: 5.742
Authors: Marco G Patti; Marcelo F Vela; David D Odell; Joel E Richter; P Marco Fisichella; Michael F Vaezi Journal: J Laparoendosc Adv Surg Tech A Date: 2016-05-24 Impact factor: 1.878
Authors: Marco E Allaix; P Marco Fisichella; Imre Noth; Bernardino M Mendez; Marco G Patti Journal: J Gastrointest Surg Date: 2013-04-25 Impact factor: 3.452
Authors: Christopher S Davis; Bernardino M Mendez; Diana V Flint; Karen Pelletiere; Erin Lowery; Luis Ramirez; Robert B Love; Elizabeth J Kovacs; P Marco Fisichella Journal: J Surg Res Date: 2013-06-29 Impact factor: 2.192
Authors: Catharina Müller; Annika Andersson-Sjöland; Hans Henrik Schultz; Leif T Eriksson; Claus B Andersen; Martin Iversen; Gunilla Westergren-Thorsson Journal: BMJ Open Respir Res Date: 2017-04-12